Bimagrumab

Modify Date: 2024-01-30 13:26:30

Bimagrumab structure	Common Name	Bimagrumab
	CAS Number	1356922-05-8	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Bimagrumab

Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness[1][2].

Name	Bimagrumab

Description	Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness[1][2].
Related Catalog	Research Areas >> Metabolic Disease
Target	ACVR2B:1.7 pM (Kd) ACVR2A:434 pM (Kd)
In Vitro	BYM338 (1 pM-1 μM; 24 h) 抑制 HEK293 细胞中 Myostatin 和 Activin A- 诱导的 Smad2/3 依赖性荧光素酶反应，IC50 值分别为 154 和 343[2]。 BYM338 (4 days) 可防止外源添加 Myostatin 或 Activin A 诱导的分化和融合抑制[2]。
In Vivo	BYM338 (6-20 mg/kg; 皮下注射，每周一次，持续 4 周) 促进所有检查肌肉的体重增加和骨骼肌肥大，包括慢速、快速和混合肌肉[2]。 BYM338 (5-20 mg/kg；皮下注射，每周一次，持续 14 天) 可防止糖皮质激素诱导的小鼠肌肉萎缩[2]。
References	[1]. Heymsfield SB, et, al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2033457. [2]. Lach-Trifilieff E, et, al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014 Feb;34(4):606-18.